Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) COO Frederic Pla acquired 20,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were purchased at an average price of $4.60 per share, for a total transaction of $92,000.00. Following the transaction, the chief operating officer now directly owns 20,000 shares of the company’s stock, valued at $92,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Akoya Biosciences Trading Up 3.2 %
Shares of NASDAQ AKYA traded up $0.14 during mid-day trading on Monday, reaching $4.45. The company had a trading volume of 174,171 shares, compared to its average volume of 166,084. The business’s 50-day moving average is $6.15 and its 200-day moving average is $7.05. The company has a current ratio of 3.37, a quick ratio of 2.94 and a debt-to-equity ratio of 0.90. The stock has a market cap of $217.79 million, a price-to-earnings ratio of -2.30 and a beta of 1.17. Akoya Biosciences, Inc. has a 52 week low of $4.28 and a 52 week high of $14.38.
Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.07). Akoya Biosciences had a negative return on equity of 123.30% and a negative net margin of 89.82%. The company had revenue of $23.52 million during the quarter, compared to the consensus estimate of $22.17 million. Equities analysts expect that Akoya Biosciences, Inc. will post -1.64 earnings per share for the current year.
Institutional Trading of Akoya Biosciences
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on AKYA shares. Morgan Stanley cut their price objective on shares of Akoya Biosciences from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 8th. BTIG Research cut their price objective on shares of Akoya Biosciences from $14.00 to $11.00 in a research report on Tuesday, August 8th. Finally, Stephens cut their price objective on shares of Akoya Biosciences from $16.00 to $14.00 in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $14.33.
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
- Five stocks we like better than Akoya Biosciences
- What is a Special Dividend?
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Choose Top Rated Stocks
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- Golden Cross Stocks: Pattern, Examples and Charts
- The Top 5 Analysts Calls in September
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.